Genetic Characteristics of Metastatic Breast Cancer Patients
NCT ID: NCT04258735
Last Updated: 2020-02-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
300 participants
INTERVENTIONAL
2019-07-17
2024-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Participant (Inclusion criteria)
1. Patients who diagnosed metastatic/stage IV breast cancer
2. Patients who were not received treatment for metastatic breast cancer on palliative setting
* Process
(1) Tissue/ Blood sample
* At diagnosis, MBC tissue / blood sample (20cc) will be obtained.
* At disease progression after 1st line treatment for MBC, blood sample (20cc) will be obtained (tissue; optional)
(2) WES, RNASeq, ctDNA, Exosome
* We will analyze genomic characteritics using WES, RNASeq, ctDNA, Exosome.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer
NCT02597179
Next pErsonalized Cancer tX With mulTi-omics and Preclinical Model
NCT02141152
Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer
NCT02470819
Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer
NCT05758948
Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.
NCT02593578
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metastatic breast cancer cohort
Metastatic breast cancer with genetic tests including WES, RNASeq, ctDNA and exosome
Genomic analysis
WES, RNASeq, ctDNA, Exosome
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Genomic analysis
WES, RNASeq, ctDNA, Exosome
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who were not received treatment on palliative setting
Exclusion Criteria
* Patients who did not have any pathologic specimen at MBC diagnosis.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Young-Hyuck Im
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center, Sungkyunkwan University School of Medicine
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-05-157
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.